Mutations of the EGFR gene constitute about 43%–89% of NSCLC cases, depending on the case series, rendering the affected patients candidates for targeted treatment with EGFR‐TKIs.72, 73, 74, 75, 76, 77, 78 Although screening for EGFR mutation‐status is performed routinely, little is known about possible coexisting carcinogenic mechanisms in the population of patients featuring EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.